脂质体多柔比星治疗淋巴瘤的疗效

Clinical effcet of liposome doxorubicin in the treatment on lymphoma

目的:探讨脂质体多柔比星用于临床治疗淋巴瘤的疗效以及安全性。方法:选取90例淋巴瘤患者作为研究对象,均采用脂质体多柔比星治疗,对患者临床资料、治疗结果、随访情况等进行回顾性分析。结果:90例淋巴瘤患者治疗总有效率为74.44%,初治者总有效率(79.25%)与复治者(67.57%)相近,组间无明显差异(P>0.05)。常见不良反应为骨髓抑制、心电图异常、心功能异常等;患者随访3年生存率为62.22%,初治者(71.70%)略高于复治者(48.65%),但组间比较差异无显著性(P>0.05)。结论:采用脂质体多柔比星临床治疗淋巴癌,效果显著,不良反应较小,安全性高,建议在临床可作为治疗淋巴瘤的首选药物进行推广应用。

Objective：To explore the efficacy and safety of liposome doxorubicin to treat the lymphoma. Methods：Ninety patients with lymphoma were selected as subjects,liposome doxorubicin was applied for patients. Results：The total effective rate of 90 patients with lymphoma was 74. 44% ,the total effective rate of initial treatment（79. 25% ） was similar to that of re - treatment（67. 57% ）,no significant differences were found between groups（P〉 0. 05）. Common adverse reactions involved bone marrow suppression,abnormal electrocardiogram（ECG）,abnormal cardiac function. The survival rate of patients after 3 years of follow - up was 62. 22% ,and survival rate of patients undergoing initial treatment（71. 70% ）was slightly higher than patients undergoing re - treatment（48. 65% ）,while the differ-ence was not significant（P 〉 0. 05）. Conclusion：The liposome doxorubicin for lymphoma has obvious efficacy with less adverse reaction and high safety.